AbCellera Biologics reported that its non-hormonal menopause treatment ABCL-635 significantly reduced the frequency and severity of hot flashes in a 92-person Phase 2 trial, with the drug meeting both primary endpoints after four weeks. The results sent the company's shares surging nearly 40% in early trading.
Research involving 149 women suggests that declining levels of beneficial bacteria Lactobacillus gasseri in the aging uterine environment may contribute to fertility challenges in women over 35, pointing to potential bacterial supplement interventions.
Research from University of Cambridge and Institute of Cancer Research reveals that current NHS and NICE referral criteria fail to identify up to 95% of women under 50 who develop breast cancer within a decade. The study suggests a comprehensive risk assessment tool called BOADICEA identifies eight times more at-risk women than current family-history-based guidelines.
Multiple health sources are drawing attention to bone health management, particularly for women over 40, addressing both calcium deficiency risks and the dangers of excessive calcium supplementation that can lead to serious health complications.
A two-decade study of over 65,000 postmenopausal women found that higher adherence to the Planetary Health Diet was associated with reduced risk of cardiovascular disease, coronary heart disease, stroke, and heart failure.
Healthcare providers and patients across the United States are reporting intermittent shortages of oral progesterone, a hormone widely used in fertility and menopause treatments. The supply strain reflects growing demand for hormone replacement therapy.
After more than a decade of discussion, polycystic ovary syndrome (PCOS) has been officially renamed polyendocrine metabolic ovarian syndrome (PMOS) through a global consensus process involving patients and clinicians. The change affects a condition impacting approximately 170 million women worldwide and is expected to improve diagnosis and treatment.
A global consortium of healthcare experts has officially renamed Polycystic Ovary Syndrome (PCOS) to Polyendocrine Metabolic Ovarian Syndrome (PMOS), a change affecting over 170 million women worldwide. Health experts say the new name better reflects the condition's systemic nature and is expected to improve diagnosis and treatment.
